Table 1.

Key inclusion and selected exclusion criteria of the PERSPECTIVE Trial, which will enroll 592 participants for its primary outcome measure of change from baseline in the GCCS [11]

Inclusion criteria

Selected exclusion criteria

Chronic heart failure with current symptoms NYHA class II–IV Left ventricular ejection fraction > 40% NT-pro BNP ≥ 125 pg/mL at screening visit Patient with evidence of adequate functioning to complete study assessments

Patients with a clinical diagnosis of Alzheimer’s disease or other dementia syndromes or any indication for or current treatment with cholinesterase inhibitors and/or another prescription dementia treatment (i.e., memantine) Mini-Mental State Examination score less than 24 at screening Clinically significant cerebral pathology that may impact cognition as assessed by central MRI reader Inability to perform cognitive battery or other study evaluations

GCCS CogState Global Cognitive Composite Score, MRI magnetic resonance imaging, NT-proBNP N-terminal prohormone of brain natriuretic peptide, NYHA New York Heart Association, PERSPECTIVE Prospective Evaluation of Cognitive Function in Heart Failure: Efficacy and Safety of Entresto compared to Valsartan on Cognitive Function in Patients with Chronic Heart Failure and Preserved Ejection Fraction